GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Alere Inc (NYSE:ALRPRB.PFD) » Definitions » Enterprise Value

Alere (ALRPRB.PFD) Enterprise Value : $4,003.79 Mil (As of Dec. 14, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Alere Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Alere's Enterprise Value is $4,003.79 Mil. Alere's EBIT for the trailing twelve months (TTM) ended in Jun. 2017 was $-54.14 Mil. Therefore, Alere's EV-to-EBIT ratio for today is -73.96.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Alere's Enterprise Value is $4,003.79 Mil. Alere's EBITDA for the trailing twelve months (TTM) ended in Jun. 2017 was $212.53 Mil. Therefore, Alere's EV-to-EBITDA ratio for today is 18.84.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Alere's Enterprise Value is $4,003.79 Mil. Alere's Revenue for the trailing twelve months (TTM) ended in Jun. 2017 was $2,332.93 Mil. Therefore, Alere's EV-to-Revenue ratio for today is 1.72.


Alere Enterprise Value Historical Data

The historical data trend for Alere's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alere Enterprise Value Chart

Alere Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alere Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alere's Enterprise Value

For the Diagnostics & Research subindustry, Alere's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alere's Enterprise Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Alere's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Alere's Enterprise Value falls into.



Alere Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Alere's Enterprise Value for the fiscal year that ended in Dec. 2016 is calculated as

Alere's Enterprise Value for the quarter that ended in Jun. 2017 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alere  (NYSE:ALRPRB.PFD) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Alere's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=4003.789/-54.135
=-73.96

Alere's current Enterprise Value is $4,003.79 Mil.
Alere's EBIT for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-54.14 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Alere's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=4003.789/212.526
=18.84

Alere's current Enterprise Value is $4,003.79 Mil.
Alere's EBITDA for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $212.53 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Alere's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=4003.789/2332.926
=1.72

Alere's current Enterprise Value is $4,003.79 Mil.
Alere's Revenue for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,332.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alere Enterprise Value Related Terms

Thank you for viewing the detailed overview of Alere's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Alere Business Description

Traded in Other Exchanges
N/A
Address
Alere, Inc. develops rapid point-of-care diagnostic devices in cardiology, infectious disease, toxicology, diabetes, oncology, and women's health. North America accounts for the largest portion of the firm's revenue (55%), followed by Europe (19%), Asia-Pacific (14%), and the rest of the world (12%). Alere's headquarters are in Waltham, Massachusetts.
Executives
John Bridgen officer: Sr VP, Business Development 51 SAWYER ROAD, C/O INVERNESS MEDICAL INNOVATIONS INC, WALTHAM MA 02453
Geoffrey S Ginsburg director 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Renuka Uppaluri officer: Senior VP, Global R&D 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Mark Gladwell officer: Senior VP, Global Operations 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Gregg J Powers director C/O QUANTUM CORPORATION, 224 AIRPORT PARKWAY SUITE 300, SAN JOSE CA 95110
Jonathan Wygant officer: VP, Controller, CAO 3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Thomas Mckillop director 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Melissa Guerdan officer: SVP, Global Quality & Reg. 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Daniella Cramp officer: Global Pres., Cardiometabolic 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Sanjay Malkani officer: Global Pres., Toxicology 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
James Jr. Roosevelt director 51 SAWYER ROAD, SUITE 200, HOPKINTON MA 02453
Robert Bernard Hargadon officer: SVP, Global Human Resources 4327 LAKE WASHINGTON BLVD NE #6208, KIRKLAND WA 98033
John F Levy director C/O INNVERNESS MEDICAL INNOVATIONS, INC., 51 SAWYER ROAD, WALTHAM MA 02453
John Quelch director C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYER RD, WALTHAM MA 02453
Carol R Goldberg director C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYERS RD, WALTHAM MA 02453

Alere Headlines

From GuruFocus

John Keeley Discloses Top New Stock Buys of Q2

By Holly LaFon Holly LaFon 09-17-2014

Corsair Capital's Analysis of Alere

By Canadian Value Canadian Value 03-06-2015

Alere Inc.: Foreign Currency Translations and the Euro

By Carmine Romano Carmine Romano 12-21-2011

Alere's Shareholders Approve Merger With Abbott

By Alberto Abaterusso Alberto Abaterusso 10-23-2016

Watsa Buys 19 Holdings in What He Calls 'Stock-Picker's Market'

By Holly LaFon Holly LaFon 11-14-2017

Mario Gabelli Comments on Alere Inc

By Vera Yuan Vera Yuan 11-21-2014

Prem Watsa Trims IBM, Berkshire Hathaway

By Tiziano Frateschi Tiziano Frateschi 02-26-2018

Diamond Hill Capital Comments on Alere Inc

By Vera Yuan Vera Yuan 03-17-2015

Mario Gabelli's Asset Fund Q3 2014 Commentary

By Vera Yuan Vera Yuan 11-21-2014